“No issues getting filled at 23c orders despite lack of liquidity” is an oxymoron.
SP is down a lot more than 64% over there last three years and justifiably. However, current price with near term catalysts makes for a good opportunity if phase three approved and partnership materialises. If they don’t occur SP under 20 cents which is probably the only part of your analysis I would agree with.
All opinion and not advice.
FDA delay for ph 3 trial approval, page-27
-
- There are more pages in this discussion • 52 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
21.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $73.55M | |||
| Open | High | Low | Value | Volume |
| 21.0¢ | 22.0¢ | 20.5¢ | $222.5K | 1.035M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 77810 | 21.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 22.0¢ | 23000 | 2 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| PAR (ASX) Chart |